CHESTERFIELD, United Kingdom, Jan. 12, 2016 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, will report first quarter fiscal 2016 results on Tuesday, Feb. 2, 2016.

http://photos.prnewswire.com/prnvar/20150105/167103LOGO

A conference call for investors will begin at 8:30 a.m. U.S. Eastern time. The call can be accessed in three ways:


    --  At the Mallinckrodt website: http://www.mallinckrodt.com/investors.
    --  By telephone: For both listen-only participants and those who wish to
        take part in the question-and-answer portion of the call, the telephone
        dial-in number in the U.S. is (877) 359-9508. For participants outside
        the U.S., the dial-in number is (224) 357-2393. Callers will need to
        provide the Conference ID of 24832248.
    --  Through an audio replay: A replay of the call will be available
        beginning at 11:30 a.m. U.S. Eastern time on Tuesday, Feb. 2, 2016, and
        ending at 11:59 p.m. U.S. Eastern Time on Tuesday, Feb. 16, 2016.
        Dial-in numbers for U.S.-based participants are (855) 859-2056 or (800)
        585-8367. Participants outside the U.S. should use the replay dial-in
        number (404) 537-3406. All callers will be required to provide the
        Conference ID of 24832248.

ABOUT MALLINCKRODT
Mallinckrodt is a global specialty biopharmaceutical and imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Contacts:
Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com

Media
 Rhonda Sciarra
Senior Manager, Communications
314-654-8618
rhonda.sciarra@mallinckrodt.com

Meredith Fischer
Senior Vice President, Communications and Public Affairs
314-654-3318
meredith.fischer@mallinckrodt.com

Logo - http://photos.prnewswire.com/prnh/20150105/167103LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-first-quarter-fiscal-2016-results-on-feb-2-2016-300203099.html

SOURCE Mallinckrodt plc